1.89

1.07% 0.02

After Hours: 1.90 0.01 +0.53%

Actinium Pharmaceuticals Inc (ATNM)

Overview News Price History Option Chain Discussions Forecast Stock Split

Actinium Pharmaceuticals Inc stock is traded at $1.89, with a volume of 1.51M. It is up +1.07% in the last 24 hours and up +71.82% over the past month. Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for patients with cancers lacking effective treatment options. Its lead product candidate is Iomab-B that is in Phase III clinical studies for myeloablation and conditioning of the bone marrow prior to a bone marrow transplant for patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older. The company is also developing Actimab-A, which is in Phase II clinical trials for the treatment of patients newly diagnosed with AML over the age of 60, as well as in Phase I clinical trials in combination with CLAG-M for patients with relapsed or refractory AML; and Actimab-M that is in Phase I clinical trials for patients with refractory multiple myeloma. Actinium Pharmaceutical, Inc. was founded in 2000 and is based in New York, New York.

Previous Close:

$1.87

Open:

$1.98

24h Volume:

1.51M

Relative Volume:

2.74

Market Cap:

$58.96M

Revenue:

$1.05M

Net Income/Loss:

$-48.82M

P/E Ratio:

-1.0328

EPS:

-1.83

Net Cash Flow:

$-47.49M

1W Performance:

+34.04%

1M Performance:

+71.82%

6M Performance:

+5.00%

1Y Performance:

-76.20%

1-Day Range:

$1.6601

$2.01

1-Week Range:

$1.3832

$2.41

52-Week Range:

$1.06

$10.24

Actinium Pharmaceuticals Inc Stock (ATNM) Company Profile

Name

Actinium Pharmaceuticals Inc

Sector

Healthcare (1167)

Industry

Biotechnology (681)

Phone

646-767-3870

Address

275 Madison Avenue, 7th Floor, New York, NY

Employee

Twitter

@actiniumpharma

Next Earnings Date

2025-03-14

Latest SEC Filings

ATNM's Discussions on Twitter

Compare ATNM with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ATNM Actinium Pharmaceuticals Inc	1.89	58.96M	1.05M	-48.82M	-47.49M	-1.83
VRTX Vertex Pharmaceuticals Inc	502.55	131.41B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	635.83	72.26B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	593.47	36.20B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	271.02	35.08B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	262.60	28.24B	3.81B	-644.79M	-669.77M	-6.24

Actinium Pharmaceuticals Inc Stock (ATNM) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-07-24	Downgrade	B. Riley Securities	Buy → Neutral
May-14-24	Initiated	Stephens	Overweight
Sep-06-23	Initiated	HSBC Securities	Buy
Feb-21-23	Downgrade	William Blair	Outperform → Mkt Perform
Sep-08-22	Initiated	Cantor Fitzgerald	Overweight
Aug-25-22	Initiated	B. Riley Securities	Buy
Nov-05-20	Initiated	Alliance Global Partners	Buy
Dec-06-17	Initiated	B. Riley FBR, Inc.	Buy
Oct-23-17	Resumed	ROTH Capital	Buy
Sep-14-17	Initiated	Maxim Group	Buy
Aug-25-16	Initiated	ROTH Capital	Buy
Feb-29-16	Initiated	H.C. Wainwright	Buy
Oct-15-15	Initiated	FBR Capital	Outperform
Oct-01-14	Initiated	MLV & Co	Buy
Jul-22-14	Initiated	Canaccord Genuity	Buy

View All

Actinium Pharmaceuticals Inc Stock (ATNM) Latest News

06:07 AM

Scott+Scott Attorneys at Law LLP Files Securities Class Action Against Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) - Business Wire

06:07 AM

08:45 AM

Breakthrough: New Prostate Cancer Treatment Achieves Near-Complete Tumor Elimination in Preclinical Study - StockTitan

08:45 AM

07:41 AM

Actinium Pharmaceuticals unveils novel prostate cancer therapy - Investing.com

07:41 AM

07:30 AM

Actinium Pharmaceuticals Provides Business Update After Presentation at Trump Mar-A-Lago Club Announcing Novel Non-PSMA Prostate Cancer Radiotherapy ATNM-400 and Outlining Revitalized Clinical Pipeline with 2025 Corporate Objectives - PR Newswire

07:30 AM

Mar 26, 2025

Small biotech joins list of health companies taking a trip to Trump's Mar-a-Lago - Endpoints News

Mar 26, 2025

Actinium stock rises ahead of Mar-a-Lago event (ATNM:NYSE) - Seeking Alpha

Mar 26, 2025

Actinium rises ahead of presentation at Trump Mar-a-Lago Club - MSN

Mar 26, 2025

Actinium Pharmaceuticals to Present Business Update at Trump Mar-A-Lago Club Today - PR Newswire

Mar 26, 2025

Actinium Pharmaceuticals’ (ATNM) Buy Rating Reaffirmed at HC Wainwright - Defense World

Mar 26, 2025

Mar 25, 2025

Actinium (ATNM) Stock Gains Momentum Amid Key Investor Event - Stocks Telegraph

Mar 25, 2025

Actinium Expands into $B Market: Expert Reveals Breakthrough Cancer Programs - StockTitan

Mar 25, 2025

Mar 24, 2025

Actinium Pharmaceuticals Announces Supply Agreement With Eckert & Ziegler For AC-225 Radioisotope To Support Comprehensive Development Activities - Marketscreener.com

Mar 24, 2025

Actinium Pharmaceuticals Announces Supply Agreement with Eckert & Ziegler for Ac-225 Radioisotope to Support Comprehensive Development Activities - Victoria Advocate

Mar 24, 2025

Did Actinium Pharmaceuticals, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky InvestigateATNM - ACCESS Newswire

Mar 24, 2025

Mar 20, 2025

Major Cancer Breakthrough: Actinium and MSK Join Forces to Transform AML Treatment Landscape - StockTitan

Mar 20, 2025

Mar 19, 2025

Actinium Unveils Massive Market Expansion: KOL to Present Breakthrough Cancer Therapy Progress - StockTitan

Mar 19, 2025

Actinium Pharmaceuticals launches clinical trial for Actimab-A in combination - Yahoo Finance

Mar 19, 2025

Mar 18, 2025

Actinium Pharmaceuticals Launches Clinical Program to Evaluate Actimab-A as Combination Cancer Therapy - Marketscreener.com

Mar 18, 2025

Actinium Pharmaceuticals Announces Clinical Trial Program in Solid Tumors Combining Actimab-A with PD-1 Checkpoint Inhibitors KEYTRUDA® and OPDIVO® - PR Newswire

Mar 18, 2025

Actinium's New Cancer Trial Combines Actimab-A With Blockbuster PD-1 Drugs500,000 Patient Opportunity - StockTitan

Mar 18, 2025

Mar 17, 2025

Game-Changing Leukemia Treatment Extends Survival 6x Longer Than Standard Therapy - StockTitan

Mar 17, 2025

Mar 14, 2025

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Receives $7.40 Consensus Price Target from Analysts - Defense World

Mar 14, 2025

Mar 13, 2025

HC Wainwright Reiterates “Buy” Rating for Actinium Pharmaceuticals (NYSE:ATNM) - Defense World

Mar 13, 2025

Mar 12, 2025

Actinium Pharmaceuticals to Participate at the 37th Annual Roth Conference - Citizentribune

Mar 12, 2025

Leading Radiotherapy Company Actinium Opens Exclusive Investor Access at ROTH 2025 - StockTitan

Mar 12, 2025

Mar 11, 2025

Actinium begins new Actimab-A trial combining Venetoclax and ASTX-727 to treat patients newly diagnosed with AML in partnership with NCI - Marketscreener.com

Mar 11, 2025

Actinium Pharmaceuticals Announces Initiation of Actimab-A Triplet Combination Frontline Trial Under NCI CRADA with Venetoclax and Taiho Oncology's Hypomethylating Agent ASTX-727 in Patients with Newly Diagnosed AML - PR Newswire

Mar 11, 2025

Revolutionary Triple-Drug Combination Trial Targets Newly Diagnosed AML Patients - StockTitan

Mar 11, 2025

Mar 03, 2025

Actinium Pharmaceuticals stock hits 52-week low at $1.07 By Investing.com - Investing.com Canada

Mar 03, 2025

Mar 01, 2025

BriaCell Therapeutics (NASDAQ:BCTX) versus Actinium Pharmaceuticals (NYSE:ATNM) Critical Analysis - Defense World

Mar 01, 2025

Feb 26, 2025

Actinium Pharmaceuticals stock hits 52-week low at $1.1 - MSN

Feb 26, 2025

Feb 23, 2025

25,000 Shares in Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Purchased by Vontobel Holding Ltd. - Defense World

Feb 23, 2025

Feb 18, 2025

Actinium Pharmaceuticals (NYSE:ATNM) Shares Up 4.5% – What’s Next? - Defense World

Feb 18, 2025

Feb 13, 2025

ATNM SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Actinium Pharmaceuticals, Inc. and Encourages Stockholders to Contact the Firm! - ACCESS Newswire

Feb 13, 2025

Feb 10, 2025

ATNM INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Actinium Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm Today! - ACCESS Newswire

Feb 10, 2025

Feb 07, 2025